ReviewEye (London, England)2024
The changing landscape of thyroid eye disease: current clinical advances and future outlook.
Review in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association between serum immunoglobulin G4 levels and Graves' ophthalmopathy: a meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Comparative effectiveness of various orbital decompression techniques in treating thyroid-associated ophthalmopathy: a systematic review and meta-analysis.BMC ophthalmology · 2024Pooled it
- Quantitative evaluation of synthetic MRI for assessing disease activity in thyroid eye disease.European radiology experimental · 2026Article
- Efficacy and safety of secondary infero-medial orbital wall decompression after orbital fat decompression in Graves' orbitopathy: A 12-year experience.Indian journal of ophthalmology · 2026Article
- Audiometric changes during teprotumumab therapy for thyroid eye disease: a prospective pilot study.Endocrine · 2026Article
- The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease.Reviews in endocrine & metabolic disorders · 2026Review
- Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization.Laryngoscope investigative otolaryngology · 2026Article
- Enhancing ocular sign detection: AI-based strategic segmentation for improved accuracy and privacy protection.NPJ digital medicine · 2026Article
- Patients with Thyroid Eye Disease Initiating Teprotumumab: A Real-World Cohort Study Using the Linked IRIS-Komodo Database.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- How to manage thyroid eye disease: recent advances - a narrative review.Drugs in context · 2026Review
- Modulation of gut microbiota in Graves' orbitopathy: Prevotella dominance and atorvastatin's impact.Microbiome · 2025Article
- Transcriptomic Profiling of Orbital Fat Tissue and Ocular Surface Wash in Active Thyroid Eye Disease Requiring Urgent Orbital Decompression.Investigative ophthalmology & visual science · 2025Article
- Predictive factors for surgical interventions following intravenous glucocorticoid pulse therapy in active moderate-to-severe thyroid eye disease.Hormones (Athens, Greece) · 2025Article
- Clinical value of dual-energy CT parameters combined with morphological features in predicting graves' ophthalmopathy.BMC medical imaging · 2025Article
- Advancing the Therapeutic Frontier in Thyroid Eye Disease.TouchREVIEWS in endocrinology · 2025Article
- Exploring thyroid eye disease in Brazil: insights from a single-center study.Archives of endocrinology and metabolism · 2025Article
- Redefining Treatment Paradigms in Thyroid Eye Disease: Current and Future Therapeutic Strategies.Journal of clinical medicine · 2025Review
- Predictive demographic and clinical features for the development of dysthyroid optic neuropathy in a multi-ethnic TED population: a retrospective cohort study.Thyroid research · 2025Article
- An Atypical Presentation of Thyroid Eye Disease in a Patient With a Remote History of Graves' Disease.Cureus · 2025Article
- Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis review aims to provide an overview of the current understanding of TED and its pathophysiology. To describe the evidence base for current consensus treatment recommendations and newer biological therapies available as well as to present future therapeutic research.
methodsWe reviewed and assessed the peer-reviewed literature placing particular emphasis on recent studies evaluating the pathophysiology of TED, landmark trials forming the basis of current management and recent clinical trials informing future therapeutics. Searched were made in MEDLINE Ovid, Embase Ovid, US National Institutes of Health Ongoing Trials Register and EU Clinical Trials Register. Keywords included: "Thyroid Eye Disease", "Graves Orbitopathy", "Thyroid Orbitopathy" and "Graves' Ophthalmopathy". RESULTS AND
conclusionsThe pathophysiology of TED involves a complex array of cellular and humoral based autoimmune dysfunction. Previous therapies have been broad-based acting as a blunt instrument on this mechanism with varying efficacy but often accompanied with a significant side effect profile. The recent development of targeted therapy, spearheaded by Teprotumumab has led to an array of treatments focusing on specific components of the molecular pathway optimising their impact whilst possibly minimising their side effect profile. Future challenges involve identifying the most effective target for each patient rather than any single agent being a panacea. Long-term safety profiles will require clarification as unintended immunological consequence downstream may become manifest as seen in other diseases. Finally, future novel therapeutics will entail significant expenditure and may lead to a divergence of available treatment modalities between healthcare systems due to funding disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.